Clinical Trial Update: Study to Evaluate the Efficacy and Safety of CDK4/6 Inhibitor SHR6390 Combined With Pyrotinib in the Treatment of HER2-positive Advanced Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating the combination of SHR6390 (CDK4/6 inhibitor) with Pyrotinib for HER2-positive metastatic breast cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Pyrotinib (pyrotinib)
• SHR6390 (SHR6390)

Snippet

Sponsor: Sun Yat-sen University | Conditions: Metastatic Breast Cancer | Phase 2 | Status: UNKNOWN